In this study, we showed that TRPM7 is strikingly upregulated in reactive astrocytes in both active and chronic active MS lesions and that TGF‐β1 treatment is able to enhance astrocytic TRPM7 expression in vitro. This evidence concerns the gene TRPM7 and myeloid sarcoma.